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IMPROVED TYPE-2 DIABETES MELLITUS OUTCOMES WITH 
PERIODONTAL TREATMENT   
 
ASHLEY ANN NONEMAKER 
ABSTRACT 
 Diabetes Mellitus (DM) and periodontal disease (PD) are both common, chronic 
and debilitating diseases. This paper will illustrate the bidirectional relationship between 
the two disease processes and how treatment of periodontal disease can improve the 
glycemic control and overall health of patients with DM. Multiple studies that will be 
discussed have shown this relationship and concluded PD treatment improves the health 
of patients with DM, especially in regards to glycemic control. Unfortunately, at this time 
there is very little data from large scale studies on this topic. The proposed study intends 
to perform a RCT to show that non-surgical PD treatment in patients with periodontal 
disease improves glycemic control, hsCRP levels, and kidney function of patients with 
diabetes mellitus. The significance of this study cannot be understated. The hypothesized 
conclusions would provide an adjunct therapy to treat DM and its complications 
potentially preventing end organ damage and progression of disease, which would help to 
improve the great healthcare burden of this disease.  
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INTRODUCTION 
Background 
Diabetes mellitus (DM) is a disease marked by hyperglycemia due to inadequate insulin 
production, insulin dysfunction or a combination thereof. According to the Centers for 
Disease Control (CDC), as of 2010, 8.3% of the United States population was affected by 
diabetes, and those patients with DM have about twice the risk of death as patients 
without DM 1. Incidence of DM continues to rise and the American Diabetes Association 
estimates the total cost of diagnosed DM in the US in 2012 at $245 billion2. Due to the 
prevalence and healthcare burden of DM, studies and trials for new and innovative 
treatment and prevention options are constantly commencing.   
Periodontal disease (PD) is a disease consisting of inflammation or infection of 
the tissues surrounding the teeth; this includes various stages of periodontitis and 
gingivitis.  
The CDC reports that more than 47.2% of Americans have PD3. Like DM, PD is 
characterized by inflammation and its’ prevalence is increasing yearly3. PD is a mostly 
preventable disease and there are currently many treatment options available to lessen the 
burden of disease and reverse damage.  
As this paper will illustrate, these two diseases share a bidirectional relationship 
worth exploring. The proposed study aims to prove the hypothesized connection between 
the diseases and justify the use of PD treatment as an important adjunct therapy for DM 
patients. 
Statement of the Problem 
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Numerous literature reviews demonstrate a relationship between periodontal health and 
glycemic control, overall health, and complications of diabetes. These reviews propose a 
correlation between the inflammatory processes of both diabetes mellitus and periodontal 
disease and their bidirectional influence on one another4 5 6. Few studies have attempted 
to demonstrate the effect periodontal treatment has on glycemic control and the overall 
health of patients with type 2 DM. Some studies do show statistically significant 
improvement after periodontal treatment in the HA1c level, the gold standard of diabetic 
measurement, while others do not. At this time, many of the studies utilize small sample 
study groups and short follow up times. Evidence proving significant improvement is 
currently lacking. Our proposed randomized control study will address the current lack of 
research in this area and possibly open a new treatment avenue for diabetic patients. 
Hypothesis 
Periodontal treatment in patients with type 2 diabetes mellitus improves glycemic control 
by decreasing HbA1c and inflammatory markers, and reduces glomerular injury 
measured by urine albumin. 
Objectives and specific aims 
The objective of this study is to identify if periodontal treatment can be used as an 
adjunct treatment to improve glycemic control of diabetic patients. The specific aims of 
the study are as followed:  
• Compare glycemic control in patients with type 2 DM after 1 year of PD 
treatment compared to the control group by measuring and comparing HbA1c 
levels over 1 year.  
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• Measure levels of the systemic inflammatory marker hsCRP in patients with type 
2 DM after 1 year of PD treatment and compare to the control group.  
• Assess kidney function in patients with type 2 DM after 1 year of PD treatment 
compared to the control group by looking at urine albumin to creatinine ratio.  
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REVIEW OF THE LITERATURE 
Overview 
Diabetes Mellitus  
Diabetes mellitus is one of the most ubiquitous chronic diseases among populations 
worldwide. It is estimated that 430 million adults will have diabetes by the year 2030.  
The prevalence of diabetes has more than doubled between the years 1980 and 2008, with 
an upward trend that is not slowing7.  
Diabetes Mellitus (DM) is a disease in which there is inadequate control of blood 
glucose levels in the serum, resulting in hyperglycemia. The hormone insulin is produced 
by beta pancreatic cells and is used to transport glucose into cells from the serum. 
Glucose can then be used for energy production intracellularly. The body is either not 
producing insulin because of autoimmune pancreatic destruction such as in type 1 DM, 
which is considered insulin-dependent diabetes; or the body is not making or responding 
to insulin appropriately, as in type 2 DM.  In the United States, it is estimated that 23.1 
million people have diagnosed diabetes and another 7.2 million have undiagnosed 
diabetes as of 20158. Type 2 DM accounts for more than 90% of these DM cases9. The 
prevalence and incidence of the disease has led to an increase in studies to establish novel 
treatments to improve the disease state and discover methods of prevention. Aside from 
the glycemic control issues diabetic patients face, they also face many dangerous 
complications of the disease leading to increased morbidity and mortality.  Diabetes can 
lead to deteriorating health of both macro and microvasculature within the patient. This 
complication may result in problems of the eyes, liver, kidneys, heart, and virtually every 
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other part of the body as the disease progresses. Common complications include diabetic 
neuropathy, retinopathy, gastroparesis, nephropathy, and atherosclerosis10. Fortunately 
there are many treatments standard for DM such insulin therapy, statin use, and lifestyle 
modifications such as diet and exercise11.  
Periodontal Disease 
Periodontal disease (PD) is an overarching term for inflammatory oral disease of the 
tissues surrounding the teeth, including the gums, bone and the periodontal ligaments. 
The term includes commonly known diseases such as periodontitis, gingivitis, and many 
others. A study by the National Health and Nutrition Examination Survey (NHANES) 
estimated that over 47% of the adult population over 30 years old in the United States has 
PD3. Periodontal disease is associated with bleeding gums, loose teeth, and dental carries, 
all of which may lead to compromised nutrition, pain, and tooth loss. Along with dental 
consequences of PD, systemic complications occur as a result of a chronic inflammatory 
state.  People with PD have been shown to have increased risk for stoke, respiratory 
disease, diabetes and other systemic diseases12. Common treatment options for PD 
include, but are not limited to, routine scaling and polishing to remove plaque and tartar, 
root planning to smooth the root leading to gum reattachment, prescription antimicrobial 
mouth rise and surgical treatment, if necessary13.  
The Relationship Between Diabetes Mellitus and Periodontal Disease  
PD and DM are chronic inflammatory diseases which both affect a large proportion of 
patients worldwide. A proposed bidirectional connection between the two disease 
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processes has been suggested by a few studies and is largely accepted6. Pro-inflammatory 
cytokines are released in inflammatory disease states, including PD, and interfere with 
insulin susceptibility as well as pancreatic -cell production of insulin14. Insulin 
resistance and -cell dysfunction are both part of the pathogenesis of DM. It is known 
that there is a higher prevalence of PD among patients with controlled and uncontrolled 
DM15,16. According to the Centers for Disease Control, young adults with DM are two 
times more likely to have PD, and adults over 45 with poorly controlled diabetes were 2.9 
times more likely than the general population1 to have PD. The exact mechanism by 
which DM makes PD worse is not known but, it is hypothesized that poor glycemic 
control is a major contributor to chronic periodontal disease because hyperglycemia 
impairs the immune system’s response to bacterial infection and causes microvascular 
changes, and decrease effective wound healing.  
Complications of Diabetes Mellitus  
The associated complications of DM are major burdens on the healthcare system 
worldwide17. In 2012, the total estimated cost of diabetes was 245 billion dollars in the 
United States2. Patients are developing diabetes at younger ages, thus increasing their 
years of exposure to hyperglycemia. The development of DM at younger ages leads to 
higher risk for the development of complications of DM and increased lifetime disease 
treatment and management costs18.  
Of the many complications associated with DM, renal and cardiac complications 
comprise a large portion of the disease and healthcare burden18. In diabetic patients, 
atherosclerotic cardiovascular disease is the leading cause of death and disability. Two-
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thirds of the deaths in diabetic patients are attributable to cardiovascular causes. Diabetes 
increases cardiovascular risk through hyperglycemia, inflammation, and dyslipidemia19. 
Renal complications are also extremely common in patients with DM. In the United 
States, about 34% of adults with DM have diabetic kidney disease. Most diabetic patients 
with chronic kidney disease (CKD) can attribute their CKD to diabetes20.  
The Effect of Periodontal Disease on Diabetic Complications  
Two long-term studies assessing the effect of PD on the morbidity and mortality of 
patients with diabetes and its complications show that PD significantly contributes to the 
morbidity associated with DM. An 11-year longitudinal, prospective study (2005) found 
that patients with severe periodontal disease and type 2 DM were 3.2 times more likely to 
die due to cardiac or renal complications21. The second, and longer, 22-year study (2007) 
examined the development of microalbuminuria and end stage renal disease (ESRD) of 
patients with type 2 DM with and without periodontitis. It was found that the patients 
with moderate and severe PD were twice as likely to develop microalbuminuria when 
compared with patients with mild or no PD. The study also showed that the patients with 
moderate and severe PD were 2.3-3.5 times more likely to develop ESRD than the 
participants with mild or no PD22. Renal and cardiac complications are common in DM 
and continue to be a concern for patients living with DM making these significant 
research findings.  
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The Effect of Diabetes Mellitus on Periodontal Disease  
Having PD worsens the health of patients with DM and inversely, having DM puts 
patients at a higher risk of having periodontal disease, thus invoking a relentless cycle12 6 
14 21 22. Furthermore, the glycemic control of patients with DM affects the prevalence of 
PD; the more uncontrolled the patient’s diabetes, the more likely they are to have PD. In 
a national survey looking at adults over the age of 45, 15.1% and 6.0% of the responders 
with poorly controlled diabetes and well-controlled diabetes had severe PD respectively. 
This was significant percentage of patients with both DM and PD in comparison with 
only 4.3% of non-diabetic patients reporting severe periodontal disease 23.  
Diabetes mellitus can also exacerbate periodontal disease through infection. DM 
is known to put patients at increased risk for infection. This is believed to be due to 
immune response dysfunction from a chronic hyperglycemic state24. DM also increases 
the prevalence and virulence of periodontal infection in patients with PD compared to 
patients without DM. This is demonstrated by a case-control study (2016) looking 
specifically at C. albicans. The study showed evidence of the presence of C. albicans in 
samples from periodontal pockets taken from patients with DM and compared that to 
samples from normo-glycemic patients. Of the samples taken, 79.2% of samples from 
patients with DM and only 20.8% of the samples from non-diabetic patients contained the 
organism. Although the sample size was small, with just 30 patients, the results were 
statistically significant and show that DM does increase the infection rate of this 
organism25. A cross-sectional study of 56 patients with type 2 DM and chronic PD found 
that there was a statistically significantly higher rate of subgingival periodontal pathogens 
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in patients with poorer glycemic control. The patients with HbA1c > 8% had significantly 
more pathogens in the biofilm samples taken from their subgingival pockets26. 
Researchers demonstrated a positive association between increased exposures to 
pathogens and risk of infection of periodontal tissues.  
HbA1c, C-reactive Protein (CRP) and Albuminuria: Measurements Used to Assess 
Diabetes Mellitus and its Associated Complications   
HbA1c is the gold standard test in diagnosing DM and monitoring glycemic control in 
diabetic patients. HbA1c is a more accurate representation of glycemic control than 
fasting blood glucose levels (FBG) because FBGs can be influenced by short term dietary 
changes and stressors, while HbA1c represents the glucose levels within the patient for 
the 120-day life cycle of the red blood cell27.  Hemoglobinopathies, the abnormal 
pathology of red blood cells, can affect the HbA1c and for this reason these patients are 
excluded from the proposed study.  
C-reactive protein (CRP) is a plasma protein that rises in response to 
inflammatory stimuli such as trauma, infection and chronic inflammatory conditions28. 
Highly sensitive CRP (hsCRP) refers to the aforementioned serum protein, but is a more 
sensitive laboratory assay than the standard CRP test. HsCRP can detect levels of serum 
CRP as low as 0.01 mg/l, and is useful to detect CRP in settings of low grade 
inflammation28. CRP serum levels below 10 g/ml are typically considered benign 
clinical findings. However, it has recently been shown that even slightly elevated CRP 
plasma levels between 3-10 g/ml put patients at risk of cardiovascular disease, and 
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metabolic syndrome29. Patients with diabetes have been demonstrated to have statistically 
significantly higher levels of hs-CRP than non-diabetic patients30.  
Treating diabetes with insulin and metformin has not been shown to significantly 
lower inflammatory markers such as hsCRP when compared to placebo treatment. This 
was demonstrated by a 14-week randomized control trial (RCT) in 2009, which recruited 
500 patients with type 2 DM and found that HbA1c was significantly decreased with 
typical diabetic medications, insulin and metformin, but no significant difference in the 
inflammatory markers could be detected31.  Although DM medical treatment is not 
proven to lower hsCRP levels, it has been shown in multiple studies that nonsurgical PD 
treatment can significantly lower inflammatory markers such as CRP32,33. This is relevant 
to the health of patients with DM because, as previously described, cardiovascular 
disease is one of the major complications of DM, and CRP is considered an independent 
risk predictor for CVD29 34. CRP levels decrease with weight loss, diet, exercise and 
medications such as aspirins and statins. In clinical practice, patients can use the CRP 
level to mark improvement of their cardiovascular health. Decreases in CRP levels 
indicate decreased CVD risk34.  
Diabetes is the leading cause of kidney disease in the United States35. As many as 
20-40% of patients with type 2 DM develop diabetic nephropathy in their lifetime36. 
Chronic kidney disease (CKD) can manifest in multiple ways, but one way to detect 
kidney disease and damage is through urine albumin levels, albuminuria. Kidney disease 
can lead to an elevated albumin excretion rate (AER) due to damage to the kidney’s 
glomerular system37. Microalbuminuria is one of the initial findings predictive of 
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microvascular damage to the kidney. Microalbuminuria is also an early sign of general 
vascular damage and is a prognostic indicator for patients with kidney disease and heart 
disease. Insulin resistance is associated with microalbuminuria, thus making AER an 
important measurement to monitor in diabetic patients. Treatment to prevent or reduce 
albuminuria could potentially prevent or reduce end organ damage to the kidney35.  
Using data from the National Kidney Foundation’s Kidney Early Evaluation Program 
(KEEP), researchers established a relationship between albuminuria in diabetic patients 
and the progression to end stage renal (ESRD) or death. They retrospectively looked at 
the records of 42,761 patients with diabetes and found that albuminuria was a strong 
predictive factor for ESRD and death. They concluded that albuminuria is a stronger 
prognostic factor for ESDR and mortality than the other commonly used diagnostic 
measurement, estimated glomerular filtration rate (eGFR). This study defined 
albuminuria using a spot urine albumin to creatinine ratio (ACR) and further 
characterized the results as microalbuminuria if the ACR was 30-300 mg/g and 
macroalbuminuria if  300 mg/g 38. A study (2012) looked at tight glycemic control, 
through a low carbohydrate diet, in type two DM patients over one year and found that 
aggressive glycemic control significantly decreases microalbuminuria within 12 months. 
Out of the 124 subjects in the study, 50 had microalbuminuria and 52% of those patients 
achieved remission36. The proposed study will use ACR to monitor kidney function and 
assess microalbuminuria in participants. To date there have been no studies done to 
directly evaluate PD treatment to the reduction of microalbuminuria, but they do show 
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increased endothelial function39. This gap in the literature will be amended by the 
proposed study.   
Measurements Used to Assess Periodontal Disease 
Periodontal examinations assess the presence or absence of PD, as well as the severity 
and progression of the disease. A systematic review in 2009 of the methods used in 
research to identify PD identified the common minimum criteria for diagnosing 
periodontitis that includes the measurements of clinical attachment loss (CAL) of 2mm 
and pocket probing depth (PPD) of  3 mm. PPD and CAL are measured using a 
periodontal probe which is graduated in millimeters. The periodontal probe is moved 
around each tooth between the tooth and gums. The probe stops when it reaches 
undamaged dento-gingival fibers at the base of the crevice. The  PPD measurement is 
recorded from the gingival margin to the deepest portion of the pocket and used for 
diagnostics40. The CAL is measured in the same manner; however, the measurement is 
taken from the cemento-enamel junction (CEJ), which is the junction between the enamel 
covering the crown of the tooth in the mouth and the cementum covering the root of the 
tooth, usually under the gums except in cases of gingival recession, to the base of the 
crevice41.  
Classifications of periodontal disease stages and measurements 
The most universally acknowledged classification system of PD is the system put forward 
by the American Academy of Periodontology (AAP). The classification system has been 
altered many times over the years and continues to be a topic of debate today. According 
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to the 1999 AAP classification system, PD can be diagnosed as slight PD if the clinical 
attachment loss (CAL) is 1-2 mm, moderate if 3-4 mm, and severe if  5 mm CAL. 
Chronic periodontitis is further categorized as localized if it affects 30% of sites or 
generalized if >30% of sites are affected41. Pocket probing depth (PPD) is not considered 
as part of the diagnostic criteria of the AAP classification system but is more commonly 
used today as part of the oral examination to aid in assessing severity and effectiveness of 
maintenance. It is important to note that studies have shown that patients are at high risk 
assessment of chronic periodontitis at  5mm PPD42. However, due to the fact that the 
PPD at which PD is established is controversial, the proposed study will utilize the 
measurement of >30% of the teeth with  3mm PPD as the measure at which patients are 
considered to have PD based on AAP recommendations41.  
Full-mouth assessments are ideal for detecting PD but can be timely and may 
cause patients discomfort. A study conducted at the Indiana University School of 
Dentistry concluded that partial-mouth assessments examining half of the mouth with 6 
sites per tooth provided a practical and sustainable alternative to a 6-site full-mouth 
examinations43. For these reasons the proposed study will utilize examination of 6 sites 
per tooth on one upper and one lower quadrant of the mouth to minimize patient 
discomfort and maximize efficiency for the study.  
Periodontal treatment options 
Periodontal treatment options include surgical, non-surgical and/or educational 
interventions. Choosing a treatment plan for patients with chronic periodontal disease can 
be complex and multifaceted. Nevertheless, there is evidence to support non-surgical 
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treatment as the mainstay of treatment. According to the American Academy of 
Periodontology (AAP) Guidelines, treatment of PD should include the least invasive, 
most prudent treatment option appropriate for the patient in question 44. Treatment is not 
one size fits all and if appropriate for the particular patient, non-surgical treatment is less 
invasive, less expensive, and can be in some cases just as effective as surgical 
treatment45. Non-surgical PD treatment includes oral hygiene instruction, scaling and root 
planning (SRP), polishing and debridement46. SRP includes supragingival and 
subgingival treatment, meaning above and below the gums without the use of surgical 
intervention47. A recent study in 2014 showed that non-surgical treatment options such as 
scaling and debridement are more effective in treating periodontal disease than oral 
hygiene instruction alone46.   
The proposed study will utilize both SRP and oral hygiene instruction in the 
treatment group. Periodontal treatment will occur every six months at the time of blood 
draws, urine collection and periodontal probe measurements. The AAP recommends 
periodontal maintenance 4 times a year for patients with established periodontal disease. 
However, due to cost and patient compliance, the proposed study will evaluate subjects 
semi-annually, which is also an effective interval for maintenance48. It is also stated that 
the recommendation should be evaluated on a case-by-case basis by the clinician, and all 
treatment plans should be tailored and up-dated for the needs of the individual patient49. 
Treatment will not be administered to participants in the proposed study if there is 
evidence of potential harm to the patient.  
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Questions about bi-directionality in treatment of PD and DM 
Treatment of periodontal disease improves periodontal disease but there is contradicting 
evidence of whether or not PD treatment improves DM. Further exploration of the 
bidirectional relationship between periodontal disease and diabetes mellitus is needed. 
This study will be used to provide more data and strengthen the case for additional 
treatment options for patients suffering from one or both of these chronic inflammatory 
diseases.  
Existing research 
Justification for the necessity of the proposed study  
 
There are a limited number of studies and meta-analyses available regarding the effect of 
non-surgical periodontal treatment on the health of diabetic patients. Most of the studies 
available look at how periodontal treatment leads to PD health improvement and the 
effect on HbA1c of type 2 diabetic patients 48 50. While the majority of these studies show 
significant improvement of both PD health and glycemic control, more high quality 
randomized control studies are needed to corroborate these results. There is a great need 
for a new study with a larger sample size, longer follow up, and quality methods that 
allow for meaningful interpretation50.  
Literature Review  
One very large prospective cohort study (2016) at the Veterans Administration looked at 
the long-term effect of PD care on HbA1c in type 2 diabetics. The study had 126,805 
participants whom all received care at the VA in the United States, had PD and type 2 
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DM. These patients were studied for an average of 1.7 years. The mean HA1c of the 
cohort increased from 7.03% to 7.21% during the study. However, within the total 
population, patients who received the baseline treatment saw reduced mean HbA1c by -
0.02% and, the participants who received periodontal maintenance treatment within 6 
months of the baseline treatment saw the mean HbA1c reduced by -0.074%.  Periodontal 
maintenance treatment reduced HbA1c by up to -0.25% in individuals. The maintenance 
treatment also increased the probability of controlling their diabetes by up to 13% in 
previously poorly controlled individuals. The resulting improvement in HbA1c seen was 
more significantly improved in individuals with a HbA1c  9.0% at the beginning of the 
study. Although the sample size of this study was more than adequate, the sample was 
not diverse; 97% of the participants were men, the average age was 64 years old and 71% 
of the participants were white48. The narrowness of the population characteristics limits 
the generalizability of the study but provides valuable insight on the effect of long-term 
periodontal treatment on the health of diabetic patients.  
A randomized control trial with 60 participants was completed in Greece (2012) 
and looked at the effect of non-surgical periodontal therapy on the levels of HbA1c as 
well as hsCRP, oxidative stress, and matrix metalloproteinase of patients with PD and 
type 2 DM. The study was run over a 6-month time period. The HbA1c was significantly 
decreased at 6 months between the intervention group by -0.72 and the control group by -
0.13. This is supportive of the proposed hypothesis for PD treatment leading to increased 
glycemic control of type 2 diabetic patients. Another value of interest in the proposed 
study is the hsCRP marker.  In this study, hsCRP at 6 months was reduced by 0.34 in the 
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intervention group and 0.08 in the control group. The hsCRP was not statistically 
significantly changed between the two groups (P = 0.06). It is interesting that in this 
study the control group received oral hygiene instruction and supra-gingival cleaning 
with the ultrasonic scaler at baseline. The intervention group also received these 
interventions but additionally received scaling and root planning of the whole mouth51. 
One could hypothesize that the control group was not a true control group because they 
received supra-gingival cleaning which may have caused their hsCRP to drop and led to 
insignificant findings between the groups. Because of the limitations the control group 
interventions caused, the proposed study will not include physical interventions at 
baseline in and will also test hsCRP before and after treatment.  
A randomized control study in 2011, looked at 134 patients with type 2 diabetes 
and the effect that non-surgical PD treatment had on inflammatory markers and metabolic 
control. The participants were randomly allocated to treatment group 1, group 2, or the 
control group. Treatment group 1 had non-surgical periodontal treatment at baseline and 
subgingival treatment at the 3-month appointment. Group 2 had the same treatment at 
baseline but had supra-gingival prophylaxis at the 3-month appointment. The control 
group had no interventions. The study looked at multiple variables including hsCRP, 
tumor necrosis factor , fasting blood glucose, HbA1c, and lipid profiles. They tested 
these factors at 1.5, 3, and 6 months after periodontal treatment52.  
HsCRP was significantly reduced in both treatment groups. At baseline, treatment 
group 1 had a mean hsCRP of 3.21 and by 6 months was reduced to 1.58. Treatment 
group 2 was also reduced from baseline of 3.09 to 1.53. The control group mean saw an 
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increase from 2.81 at baseline to 3.16 at 6 months52. The improvements in treatment 
groups 1 and 2 are clinically significant because a CRP of  3.0 is considered high risk 
for cardiovascular disease and these patients were reduced below that threshold29. 
The HbA1c decreased in both treatment groups but was not significantly lower than the 
control group. This potentially could have been due to the short follow up of only 6 
months as HbA1c is a representation of glycemic control over 120 days and the effects of 
PD treatment may not have reached their full potential by 6 months. If the trial had 
followed up with participants at a later time-interval, it would have be interesting to see if 
the HbA1c would have continued to drop and become statistically significant. The mean 
HbA1c levels, at baseline, of treatment group 1, group 2 and the control group were 7.31, 
7.29, and 7.25 respectively. At 6 months, treatment group 1 had a mean HbA1c of 7.06, 
group 2 had a mean of 6.87 and the control group had an increase to a mean of 7.38. One 
limitation of this study was that the baseline HbA1c levels are fairly low for diabetic 
patients. These levels are consistent with diabetes, however, because it is the mean of the 
group, this shows that many of the participants have fairly well controlled diabetes. This 
means that they have less room for improvement of their HbA1c than a more 
uncontrolled diabetic patient. This could have also contributed to the change in HbA1c 
not being statistically significant. The researchers admit that this study was limited 
because it was underpowered and larger RCTs are needed to further explore PD treatment 
as an intervention in DM patients in regards to all of the variables looked at52.  
A 2012 randomized control clinical trial was performed in China looking at the 
effect of scaling and root planning (SRP) and enhanced root planning (ERP) on the health 
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of 75 patients with type 2 DM and PD. The recruited patients were randomly assigned to 
the treatment or control group in a 2 to 1 ratio. All 75 patients underwent baseline labs 
including fasting blood glucose (FBG), and HbA1c as well as an oral examination. Fifty 
participants were assigned to the treatment group and were give oral health instruction, 
SRP and manual curettage after their initial evaluation. At 3 months, all participants 
again had a full evaluation of the study parameters. At that time, the treatment group was 
randomly assigned to have ERP treatment or sub-prophylaxis treatment. ERP treatment 
included repeating the full-mouth SRP treatment. The patients receiving sub-prophylaxis 
treatment received only full-mouth ultrasonic scaling without root planning. All 
parameters were again checked 3 months after the second treatment. HbA1c was 
significantly reduced by 3 and 6 months by 0.17% and 0.18% respectively, in the 
treatment group compared to the control group47.  
Because of the continued improvement in HbA1c overtime, it could be argued 
that longer follow up is needed to assess the effectiveness of multiple treatments. This is 
one of the many reasons that our proposed study will follow participants for a 12-month 
time frame. This study is unique, because they also looked at how different non-surgical 
periodontal treatments can affect the outcome of the type 2 DM patients. However, this 
finding is less applicable to the outcomes we wish to measure because they only looked 
at how the different treatments affected the PD outcomes and not the HbA1c. It would be 
meaningful in future studies to compare these two treatment methods in terms of HbA1c 
improvement. It is unclear how the different treatment methods affected the HbA1c at 6 
months compared to the control group. This study does however still support that 
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periodontal treatment does improve glycemic control in these patients and is considered 
evidence that more definitive large scale prospective RCTs are needed47.  
Another study which supports the proposed study hypothesis and simultaneously 
encourages longer study lengths was published in the Journal of Oral Science in 2015. 
This study looked at the effect of non-surgical periodontal therapy on 100 patients with 
chronic PD and type 2 DM. The study took place in India and stratified patients based on 
HbA1c. The participants were then randomly allocated to the treatment group or control 
group; 50 participants in the treatment group received SRP while the other participants 
received no treatment. HbA1c in the treatment group was assessed at baseline, 3 months 
and 6 months and was found to have a mean of 8.17, 7.49, and 7.29 correspondingly. The 
control group showed increasing HbA1c values of 7.87, 7.96. and 8.06. HbA1c continues 
to drop overtime and longer studies are need to assess the sustainability of these results. 
The limitations of this study included the small sample size and the single-center 
recruitment53.  
Summary of literature review 
The results of the existing research cited shows small but clinically significant reductions 
in HbA1c after PD treatment. The lowest risk for diabetic complications lies in the 
normal range of HbA1c, below 6.0%. In said research, this was not a value that many of 
the participants obtained. However, a prospective, multi-center, observational study in 
England, Scotland and Northern Ireland showed that a reduction in HbA1c by 1% can 
decrease the complications of diabetes by 21% over a median of 10 years54. A reduction 
in HbA1c is beneficial to diabetic patient’s health overtime, even if the reduction is 
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seemingly small. Because of the promise that the existing research shows, another RCT is 
necessary to help pioneer PD treatment as a viable option in the battle against the 
diabetes epidemic.  This treatment may not only target glycemic control but also 
improvement in markers associated with diabetic complications.  
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METHODS 
Study design 
The proposed open, prospective, randomized control trial of 3 years duration will 
examine the effect of periodontal treatment in patients with type 2 diabetes mellitus and 
concomitant periodontal disease in comparison to subjects not receiving periodontal 
treatment.  
Study population and sampling 
Patients will be recruited from Boston Medical Center Endocrinology Clinic in the adult 
diabetes program. All patients who attend the clinic will be screened for eligibility. The 
enrollment will be a one year time period. Patients who meet medical criterial will have 
blood drawn, urine collected and will be referred to Boston University Henry M. 
Goldman School of Dental Medicine to be evaluated for the diagnosis of PD.  
The sample size necessary for this trial is 46 participants in each group for a 95% 
confidence interval. A minimum of 92 participants are needed, however due to drop out 
and other unforeseen circumstances a minimum of 120 should be enrolled55. This sample 
size is calculated from an  level of 0.05, a  level of 80% and a measurement of 
meaningful change of 0.352. These values are based upon the primary outcome 
measurement of the change in HbA1c.  
Table 1. Inclusion Criteria and Exclusion Criteria for this RCT.  
Inclusion Criteria  Exclusion Criteria 
Must be 18 or older to participate Limited life expectancy due to age or 
medical conditions 
Type 2 DM diagnosed by a physician for 
 1 year  
Pregnancy 
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Stable on diabetic medications with no 
changes for   3 months prior to 
enrollment 
Daily use of NSAIDS, with the exception of 
low dose aspirin  325 mg per day  
HbA1c  7.0% and  14.0 Use of immunosuppressive medications 
No changes of diabetic medications for 
the duration of the study unless it is 
medically necessary 
Patients with significant bleeding risk  
 Patients on dialysis as kidney failure may 
falsely increase HbA1c 
 Hemoglobinopathies  
 Extensive oral health issues outside the 
scope of the study, including: < 20 teeth, 
oral abscesses, severe tooth decay needing 
multiple procedures, etc.  
 Excessive alcohol intake defined as:  
> 3 drinks per day for women and no more 
than 7 drinks per week  
> 4 drinks per day for men and no more 
than 14 drinks per week  
 Recent PD treatment within the last year  
 
Treatment  
The participants will be randomly assigned to either the control group or the treatment 
group. Patients in both groups will have their initial labs drawn and urine collected at 
BMC to document their initial HbA1c, CRP, and urine protein levels.  All participants 
will be scheduled for an appointment to have their periodontal status assessed by trained 
dental clinicians at the Boston University Henry M. Goldman School of Dental Medicine 
using periodontal probing in 2 quadrants, one upper and one lower 43. The participants 
allocated to the control group will have no further interventions but will continue to have 
their blood, urine and periodontal probing tested at 6, and 12 months to be used as the 
comparison for the treatment arm27. The treatment group participants will follow the 
same schedule as the control group with the added intervention of having periodontal 
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treatment by the dental clinicians at 6, and 12 months48. Periodontal therapy will include 
scaling, polishing, debridement, and root planning as needed and dental hygiene teaching 
which includes instruction on proper brushing and flossing techniques46.  
Study variables and measures 
The following table outlines the key variables being tested within this study and how they 
will be measured objectively.  
Table 2. Project Variables and Measurement Tools  
Outcome Variables  Measurement Technique or Instruments 
HbA1c27 48 51 HbA1c test - blood 
hsCRP 28 29 30 32 33 hsCRP test - blood 
Urine Albumin to Creatinine Ratio35 36 37 38 Urine sample 
Periodontal Probe Depth 40 41 Periodontal probe 
 
Recruitment 
The participants needed for this study will be found at the Boston Medical Center 
Endocrinology Clinic as described in the study population and sampling section above. 
This clinic has a large volume which will provide a large sample size and diverse 
population from which we will obtain the participants.   
To provide incentive to participants, all dental care will be free of cost to the patient. 
However, because this will be a randomized control study, the patients in the control 
group will not be receiving the incentivized care. To assure their continued participation, 
those control patients who fulfill the study tests will be offered one year of comparable 
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dental care after the study is complete. This will only be revoked if the care provided is 
found to be harmful to the participants’ health. Patients in the control group will receive 
dental care prior to 1 year if it is found that they are in imminent danger due to their 
dental health.  
Data collection 
The participants will all be patients of BMC and will all have assessable electronic 
medical records (EMR). The dental records will have to be recorded at each visit on 
paper charts. The record will show which procedures or treatments the patient received at 
that visit and the periodontal probe depths in 2 quadrants, one upper and one lower. 
These quantitative depths will be transferred to an excel spreadsheet to assist in 
calculations during the analysis.  
Data analysis 
All of the variables in the proposed study, including HbA1c, hsCRP, urine albumin to 
creatinine ratio and periodontal probe depth are continuous and will be analyzed using 
repeated measures ANOVA to assess the difference in the individual participants’ values 
before, during and after 1 year of treatment or monitoring. A Wilcoxon Rank-Sum test 
will be used to compare the median change, of all the previously mentioned variables, 
between the control group and the treatment group. All of the proper means, medians, 
ranges and, standard deviations of the continuous variables will be calculated as needed. 
Due to the right skewed nature of HbA1c, a Spearman’s correlation coefficient will be 
utilized to determine the rank correlation between severity of participants’ initial 
glycemic control defined by HbA1c and the mean change of HbA1c at the conclusion of 
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the study. Stratified analysis will be used to account for any cofounders identified among 
the study population recruited such as age and number of diabetic medications. 
Timeline and resources 
The proposed study will take 3 years to complete. Patient recruitment will occur for the 
entirety of year one. Patients will begin 12 months of monitoring or treatment at the time 
of enrollment. By the end of year two all participants will have completed 12 months of 
monitoring or treatment. Year three will be used to analyze the data and document the 
results.  By the end of year three all of the control participants will have 12 months of 
comparative dental treatment. IRB submission and approval will be obtained prior to the 
study commencement.  
Table 3. Study Timeline.  
Year 1 Year 2 Year 3 
Participant enrollment 
begins January 2019 
Intervention begins after 
enrollment 
Enrollment ends January 
2020  
Intervention continues  
Intervention ends January 
2021 
Data analysis & result 
reporting occurs 
 
To complete this study an endocrinology co-investigator will be needed for 
recruitment and ongoing monitoring of DM. Space at the dental school and trained dental 
clinicians will be needed to provide the dental care. Each participant needs to be assessed 
and three times during the intervention year, and each participant will receive PD 
treatment three times in their intervention or compensatory year. This will approximately 
take 360 hours of work by skilled dental clinicians and will require between $35.31 per 
hour to pay the clinicians56. This will approximately cost $12,711.60 total. Added costs 
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may occur if more invasive procedures and are needed on an individual participant basis 
because a dentist or dental hygienist will need to be paid for services. 
The principal investigator, co-investigator, research coordinator and statistician 
will need to paid for their time and services as well. Wages will be determined on a 
person-to-person basis.  
Each participant will need three sets of the laboratory values throughout the study. 
This will cost approximately $600.57 per person and about $72,068.40 total. The 
laboratory costs are broken down below in table __ and were based on the Quest 
Diagnostics billing for Massachusetts for patients without insurance57. Periodontal probe 
testing does not accrue an extra cost not already accounted for in the hourly wages.  
Table 4. Cost of lab tests from Quest Diagnostics Billing in Massachusetts without 
insurance.  
Laboratory Test Cost 
HbA1c $74.25 
hsCRP $50.00 
Urine albumin $37.97 
Urine creatinine $37.97 
 
Institutional Review Board 
This proposal will be submitted for full-board IRB approval prior to starting the study. 
Full-board review is needed because the population at BMC is underserved and these 
participants may not be able to get dental care otherwise. Full-board review is also 
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necessary due to the invasive dental procedures that will be employed throughout the 
study.   
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CONCLUSION 
Discussion 
Periodontal health plays an important role in the overall health of patients with diabetes. 
Currently, there is limited information and very few RCTs illustrating the direct effect of 
nonsurgical PD treatment on biomarkers of disease such as HbA1c, hsCRP, and urine 
albumin to creatinine ratio. The proposed RCT will look at these markers directly and 
will compare a control group to a treatment group in a significant way.  
This study is limited due to being a unicenter study. In the future, it is important 
to repeat this study as a larger multicenter study. The generalizability of this study will be 
excellent because BMC serves a diverse metropolitan population of all races, ages, and 
socioeconomic status. This can also pose as an obstacle to IRB approval because the 
population at BMC can be considered a vulnerable population. However, ethically this 
study amends the control group’s year of observations by providing comparable care at 
the conclusion of the study that they may not otherwise have been able to obtain. This 
trial will have a full 12 months of follow up which is longer than many of the 
aforementioned studies on the hypothesis. The length of the study may help further 
support of PD treatment as an on-going therapy for diabetic health, and not just as an 
acute adjunct therapy. This RCT will have a larger sample size, with 120 enrolled 
participants, than many of the currently available studies. Even larger studies can be 
justified in the future to create a narrower margin of error. Overall the proposed trial will 
fill the gaps in the literature with a more reliable and generalizable method than previous 
studies.  
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Summary  
Periodontal treatment may be an important tool to combat systemic diseases, specifically 
diabetes mellitus. PD treatment has been shown to lower hbA1c, hsCRP and improve 
kidney function27- 33 48 51. These biomarkers are all indicative of health status and disease 
management. By completing the proposed study, we hope to prove that HbA1c and 
hsCRP are improved with PD treatment in patients with DM. We also hope to show an 
effect of  PD treatment on albumin to creatinine ratio, helping us to better understand 
kidney complications in diabetic patients. This literature review has revealed that there 
are many connections between PD treatment and systemic diseases like cardiovascular 
disease and end stage renal disease, but very few regarding DM which can eventually 
lead to the diseases mentioned. By lowering these laboratory values in our patients and 
improving their overall health, through PD treatment, we may be able to not only treat 
disease, but prevent it. If we can provide enough evidence of the benefits of PD treatment 
to costly medical issues then the healthcare system will be forced to reevaluate the 
coverage of these procedures in the future. 
Clinical and/or public health significance  
The potential implications of the above conclusions would provide an additional means 
of treatment for glycemic control for patients with diabetes. This could lessen the 
progression of end organ damage, devastating complications of DM and the overall 
burden of diabetes on the healthcare system. Using PD treatments as an additional 
treatment method for DM could improve the life of patients worldwide due to the dental 
and medical benefits illustrated in this proposal. 
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